CAS 105462-24-6|Risedronic acid

Introduction：Basic information about CAS 105462-24-6|Risedronic acid, including its chemical name, molecular formula, synonyms, physicochemical properties, and safety information, etc.

Table of Contents

1. Names
2. Risedronic acid BiologicalActivity
3. Chemical & Physical Properties
4. Safety Information
5. Customs
6. Synonyms

Common Name	Risedronic acid
CAS Number	105462-24-6	Molecular Weight	283.112
Density	1.9±0.1 g/cm3	Boiling Point	692.3±65.0 °C at 760 mmHg
Molecular Formula	C₇H₁₁NO₇P₂	Melting Point	/
MSDS	/	Flash Point	372.5±34.3 °C

Names

Name	Risedronic Acid
Synonym	More Synonyms

Risedronic acid BiologicalActivity

Description	Risedronic acid (Risedronate ) is a pyridinyl biphosphonate which inhibits osteoclast-mediated bone resorption.Target: OthersRisedronate, which was promoted in Croatia a few months ago, is the latest (III) generation of bisphosphonates, the most efficient anti-resorption drugs that inhibit osteoclast-mediated bone resorption and change the bone metabolism. Risedronate is hence the first line of bisphosphonates for the reduction of vertebral and non-vertebral fracture risks in postmenopausal women with osteoporosis or those with a high risk of osteoporosis. It also efficiently prevents bone loss or improves bone density in men and women on a long-term corticosteroid therapy .The administration of 20 and 25 mg/kg risedronate for 4 days led to decreases of parasitemia of 68.9% and 83.6%, respectively. On the seventh day of treatment the inhibitions were 63% and 88.9% with 20 and 25 mg/kg, respectively. After recovering the parasitemia, a dose-response curve was obtained for estimating the ID50 (dose causing 50% inhibition), equivalent to 17 ± 1.8 mg/kg after 7 days of treatment. Four days after the interruption of treatment (11 days postinfection), the parasitemias of the groups treated with 10, 15, 20, and 25 mg/kg/day were 15.3%, 15.9%, 15.2%, and 5.7%, respectively. Conversely, the group that received PBS presented parasitemia of 25.6%. Among the groups treated with risedronate, only the animals that received 25 mg/kg had a significant inhibition of 77.8% (see Table S1 in the supplemental material), demonstrating that even after treatment discontinuation, the parasitemia of the animals remained low in relation to that of the controls .
Related Catalog	Signaling Pathways >>Others >>OthersResearch Areas >>Others
References	[1]. Giljevic Z, et al. Treatment of osteoporosis by risedronate-- speed, efficacy and safety. Reumatizam. 2006;53(2):66-71. [2]. Jordao FM, et al. In vitro and in vivo antiplasmodial activities of risedronate and its interference with protein prenylation in Plasmodium falciparum. Antimicrob Agents Chemother. 2011 May;55(5):2026-31.

Description

Risedronic acid (Risedronate ) is a pyridinyl biphosphonate which inhibits osteoclast-mediated bone resorption.Target: OthersRisedronate, which was promoted in Croatia a few months ago, is the latest (III) generation of bisphosphonates, the most efficient anti-resorption drugs that inhibit osteoclast-mediated bone resorption and change the bone metabolism. Risedronate is hence the first line of bisphosphonates for the reduction of vertebral and non-vertebral fracture risks in postmenopausal women with osteoporosis or those with a high risk of osteoporosis. It also efficiently prevents bone loss or improves bone density in men and women on a long-term corticosteroid therapy .The administration of 20 and 25 mg/kg risedronate for 4 days led to decreases of parasitemia of 68.9% and 83.6%, respectively. On the seventh day of treatment the inhibitions were 63% and 88.9% with 20 and 25 mg/kg, respectively. After recovering the parasitemia, a dose-response curve was obtained for estimating the ID50 (dose causing 50% inhibition), equivalent to 17 ± 1.8 mg/kg after 7 days of treatment. Four days after the interruption of treatment (11 days postinfection), the parasitemias of the groups treated with 10, 15, 20, and 25 mg/kg/day were 15.3%, 15.9%, 15.2%, and 5.7%, respectively. Conversely, the group that received PBS presented parasitemia of 25.6%. Among the groups treated with risedronate, only the animals that received 25 mg/kg had a significant inhibition of 77.8% (see Table S1 in the supplemental material), demonstrating that even after treatment discontinuation, the parasitemia of the animals remained low in relation to that of the controls .

Related Catalog

Signaling Pathways >>Others >>OthersResearch Areas >>Others

References

[1]. Giljevic Z, et al. Treatment of osteoporosis by risedronate-- speed, efficacy and safety. Reumatizam. 2006;53(2):66-71.

[2]. Jordao FM, et al. In vitro and in vivo antiplasmodial activities of risedronate and its interference with protein prenylation in Plasmodium falciparum. Antimicrob Agents Chemother. 2011 May;55(5):2026-31.

Chemical & Physical Properties

Density	1.9±0.1 g/cm3
Boiling Point	692.3±65.0 °C at 760 mmHg
Molecular Formula	C₇H₁₁NO₇P₂
Molecular Weight	283.112
Flash Point	372.5±34.3 °C
Exact Mass	283.001068
PSA	167.80000
LogP	-2.94
Vapour Pressure	0.0±2.3 mmHg at 25°C
Index of Refraction	1.651
InChIKey	IIDJRNMFWXDHID-UHFFFAOYSA-N
SMILES	O=P(O)(O)C(O)(Cc1cccnc1)P(=O)(O)O
Storage condition	2~8°C

Safety Information

Hazard Codes	Xi
WGK Germany	3.0
HS Code	2933399090

Customs

HS Code	2933399090
Summary	2933399090. other compounds containing an unfused pyridine ring (whether or not hydrogenated) in the structure. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0%

Synonyms

Actonel

Phosphonic acid, [1-hydroxy-2-(3-pyridinyl)ethylidene]bis-

[1-Hydroxy-2-(3-pyridinyl)-1,1-ethanediyl]bis(phosphonic acid)

(1-hydroxy-1-phosphono-2-pyridin-3-ylethyl)phosphonic acid

(1-hydroxy-2-pyridin-3-ylethane-1,1-diyl)bis(phosphonic acid)

MFCD00867080

T6NJ C1XQPQQO&PQQO

[1-Hydroxy-2-(3-pyridinyl)ethylidene]bisphosphonic acid

2-(3-Pyridinyl)-1-hydroxyethanediphosphonic acid

[1-Hydroxy-2-(3-pyridinyl)ethylidene]bis(phosphonic acid)

Risedronic acid

[1-Hydroxy-2-(pyridin-3-yl)ethane-1,1-diyl]bis(phosphonic acid)

Atelvia

Recommended......